Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320791 | 0.94 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 | |
| SCHEMBL21107395 | 0.94 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 | |
| Hydrochloric Acid SCHEMBL5966938 | 0.92 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 | |
| Hydrochloric Acid SCHEMBL5967498 | 0.92 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 | |
| SCHEMBL1908662 | 0.92 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 | |
| SCHEMBL493715 | 0.92 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 | |
| SCHEMBL13387500 | 0.92 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 | |
| Hydrochloric Acid SCHEMBL31601633 | 0.90 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 | |
| SCHEMBL24102991 | 0.86 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 | |
| SCHEMBL29028066 | 0.86 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1NPSR1TSHRMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103880768-A | Chemical synthesis method of 3-cyclobutylmorpholine | UNIV NANTONG | 2014-06-25 | — | — | CN | claimed |
| CN-103880768-A | Chemical synthesis method of 3-cyclobutylmorpholine | UNIV NANTONG | 2014-06-25 | — | — | CN | disclosed |
| EP-1467989-B1 | PROLINE COMPOUNDS AS NS3-SERINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF HEPATITIS C VIRUS INFECTION | SCHERING CORP (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-1773868-B1 | SUBSTITUTED PROLINES AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| US-7425576-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7342041-B2 | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070142300-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | MERCK SHARP & DOHME LLC | 2007-06-21 | — | — | US | disclosed |
| US-7205330-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005085242-A1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142300-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SERPINB1, HAVCR2, HPN | L3MBTL1 2488/4885ALDH1A1 1238/4885NPSR1 3549/4885 |
| US-20070032434-A1 | used for the treatment or prevention of HCV or amelioration the symptoms of hepatitis C infection, by modulating the interaction of an HCV polypeptide with HCV proteases | HAVCR2, ENPEP, SERPINB1 | L3MBTL1 3140/4885ALDH1A1 794/4885NPSR1 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.